Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices. We employ more than 4300 people in Hungary and abroad. In the 2015/2016 business year, our net sales revenue was EUR 536.3 million. As an R&D-driven company that is primarily known for its high quality, value-added generic products, Egis devotes more than 10% of its consolidated turnover, more than EUR 42 million to research and development yearly, which also qualifies as one of the largest amounts spent on R&D among all the industrial companies of Central and Eastern Europe. The company has more than 3400 drug registrations in Hungary and abroad. In the 2015/2016 business year Egis launched 7 new product lines in its markets and the companyÍs product portfolio consisted of 595 products that belong to 161 product lines and contain 145 kinds of active ingredients. While still the traditional therapeutic areas like cardiovascular and central nervous systems together with allergy, oncology and urology account for the greatest share of the companyÍs sales revenue, Egis continuously opens towards new therapeutic areas, including gynecology and in 2013 it launched EuropeÍs first biosimilar monoclonal antibody.